The Comparison of Nasaleze and Mometasone Nasal Spray to Control the Symptoms of Allergic Rhinitis

Authors

1 Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Nasal corticosteroids are the main drug class for the treatment of allergic rhinitis, and their long-term continuous use can be problematic. The current study aimed to compare the use of Nasaleze and mometasone nasal spray in patients with allergic rhinitis. Materials and Methods: In this study, 64 patients were studied in two groups of 32 patients. Nasaleze was used for the first group and mometasone for the second group for 4 weeks. The severity of sneezing, runny nose, tearing, nasal congestion, itchy eyes, and scratchy throat were evaluated at the onset of the study, and also 14 and 28 days after treatment in the form of a single-blind study. Statistical analysis was performed using SPSS Software (SPSS Inc., Chicago, IL, USA, Version 20). Results: The severity of allergic rhinitis symptoms had a significant difference in both groups of Nasaleze and mometasone at three times. Furthermore, in the Nasaleze group, the intensity of tearing significantly reduced 14 and 28 days after treatment compared to the mometasone group. In addition, the mean pretreatment score of allergic had no significant difference in the two groups neither14 days nor 28 days after the treatment. Conclusion: The efficacy of Nasaleze nasal spray is very similar to that of mometasone nasal spray to control the symptoms of allergic rhinitis. Therefore, Nasaleze nasal spray can be a suitable alternative for nasal corticosteroids in children older than 18 months, pregnant and lactating women.

Keywords

1.
Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, et al. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81(5 Pt 2):478-518.  Back to cited text no. 1
    
2.
Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 2008;122:S1-84.  Back to cited text no. 2
[PUBMED]    
3.
International Rhinitis Management Working G. International consensus report on the diagnosis and management of rhinitis. Munksgaard; 1994.  Back to cited text no. 3
    
4.
Ng MLS, Warlow RS, Chrishanthan N, Ellis C, Walls R. Preliminary criteria for the definition of allergic rhinitis: A systematic evaluation of clinical parameters in a disease cohort (I). Clin Exp Allergy 2000;30:1314-31.  Back to cited text no. 4
    
5.
Bouic PJD. A Review of the Efficacy and Safety of NasalezeTM in the Prevention and Management of Allergic Rhinitis. Open Allergy J 2008;1:1-4.  Back to cited text no. 5
    
6.
Settipane RA, editor. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy and Asthma Proceedings; 2001. OceanSide Publications, Inc.  Back to cited text no. 6
    
7.
Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, et al. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518.  Back to cited text no. 7
    
8.
Emberlin JC, Lewis RA. A double blind, placebo-controlled cross over trial of cellulose powder by nasal provocation with Der p1 and Der f1. Curr Med Res Opin 2007;23:2423-31.  Back to cited text no. 8
[PUBMED]    
9.
Josling P, Steadman S. Use of cellulose powder for the treatment of seasonal allergic rhinitis. Advances in Therapy 2003;20:213-9.  Back to cited text no. 9
[PUBMED]    
10.
Emberlin JC, Lewis RA. A double blind, placebo controlled trial of inert cellulose powder for the relief of symptoms of hay fever in adults. Curr Med Res Opin 2006;22:275-85.  Back to cited text no. 10
[PUBMED]    
11.
Fathololoumi M R DAL, Ramezankhani O, Nouhi S, Fattahi Bafghi A, Goljanian A. Comparison of systemic and local corticosteroids on the clinical and laboratory parameters in patients with perennial allergic rhinitis Research in Medicine 2010;34:92-7.  Back to cited text no. 11
    
12.
Galant SP, Melamed IR, Nayak AS, Blake KV, Prillaman BA, Reed KD, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2-and 3-year-old patients. Pediatrics 2003;112:96-100.  Back to cited text no. 12
    
13.
Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000;105:e23-e.  Back to cited text no. 13
    
14.
Ellegayrd EK, Hellgren M, Karlsson NG. Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. Clinical Otolaryngology & Allied Sciences 2001;26:394-400.  Back to cited text no. 14
    
15.
Blaiss MS, editor. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy and asthma proceedings; 2007. OceanSide Publications, Inc.  Back to cited text no. 15